Tag: AstraZeneca
AstraZeneca, Daiichi’s Enhertu steps into the FDA’s fast lane for new...
AstraZeneca and Daiichi Sankyo are rapidly gaining traction for their Enhertu in HER2-positive breast cancer. Next up? An early chance at expanding the blockbuster-to-be into...
AstraZeneca puts a time limit on its COVID-19 ‘no-profit’ pledge: report
As more than a half-dozen pharma companies race to develop vaccines to fight COVID-19, AstraZeneca has stood out for its pledge that it won’t...
AstraZeneca eyes less-frequent Imfinzi dosing with FDA ‘priority’ boost
Merck’s Keytruda recently became the only member of the PD-1/PD-L1 class with an FDA nod for less-frequent dosing—but AstraZeneca doesn’t intend to let it...
AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose...
We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That...
AstraZeneca scores speedy FDA review for Farxiga based on ‘innovative’ heart...
AstraZeneca has already taken impressive Farxiga heart failure outcomes results and parlayed them into a watershed approval. Looking at Farxiga's future in a competitive...
AstraZeneca reaches supply deal with Brazilian government to produce millions of...
As COVID-19 continues to rampage across the globe, Brazil stands alongside the U.S. as the countries hardest hit with new infections and deaths. But...
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine...
AstraZeneca has picked up manufacturing partners at a rapid clip with a goal to produce 2 billion doses per year of the University of...
AstraZeneca CEO Soriot says fast-tracked COVID-19 shot will protect for just...
AstraZeneca, advancing a COVID-19 vaccine from the University of Oxford, is among global frontrunners in the worldwide hunt for a viable vaccine. Now, the drugmaker’s CEO...
AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of...
AstraZeneca made waves last week when it signed a massive $750 million deal to ramp production of a University of Oxford COVID-19 vaccine up...
Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests...
As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to...
